---
title: "Skyrizi (risankizumab-rzaa) in plaque psoriasis: Pharmacology questions"
description: "Pharmacology questions on Skyrizi (risankizumab-rzaa) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Skyrizi work (mechanism of action)? How long does Skyrizi stay in your system (half-life)? What are the inactive ingredients in Skyrizi? 3 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/pharmacology"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Skyrizi (risankizumab-rzaa) in plaque psoriasis: Pharmacology questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Skyrizi](https://www.skyrizihcp.com/prescribinginfo)

Pharmacology questions that apply to every indication of Skyrizi are on [Skyrizi (risankizumab-rzaa), all indications: Pharmacology](https://www.evicenter.com/medical-information/skyrizi/pharmacology).

## Mechanism

<a id="skyrizi-mechanism"></a>

### How does Skyrizi work (mechanism of action)?

> “Risankizumab-rzaa is a humanized IgG1 monoclonal antibody that selectively binds to the p19 
> subunit of human IL-23 cytokine and inhibits its interaction with the IL-23 receptor. IL-23 is a 
> naturally occurring cytokine that is involved in inflammatory and immune responses.  
> Risankizumab-rzaa inhibits the release of pro-inflammatory cytokines and chemokines.”

Source: [SKYRIZI: Prescribing information, page 18, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=18)

> “AN IL-23 INHIBITOR THAT SELECTIVELY BINDS TO THE P19 SUBUNIT<sup>1,2</sup>”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Mechanism of Action, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/dosing/mechanism-of-action#:~:text=AN%20IL%2D23%20INHIBITOR%20THAT%20SELECTIVELY%20BINDS%20TO%20THE%20P19)

## Pharmacokinetics

<a id="skyrizi-half-life"></a>

### How long does Skyrizi stay in your system (half-life)?

> “The estimated systemic clearance (inter-subject CV%) was 0.31 L/day (24%) and 0.30 L/day 
> (34%) and terminal elimination half-life was approximately 28 days and 21 days in subjects with 
> plaque psoriasis and Crohn’s disease, respectively.”

Source: [SKYRIZI: Prescribing information, page 19, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=19)

> “The absolute bioavailability of risankizumab-rzaa was estimated to be 74 to 89% following 
> subcutaneous injection. In healthy subjects, following administration of a single subcutaneous 
> dose, Cmax was reached by 3 to 14 days.”

Source: [SKYRIZI: Prescribing information, page 19, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=19)

> “In subjects with plaque psoriasis treated with 150 mg subcutaneously at Weeks 0, 4, and every 
> 12 weeks thereafter, steady-state peak concentration (Cmax) and trough concentration (Ctrough) are 
> estimated to be 12 mcg/mL and 2 mcg/mL, respectively.”

Source: [SKYRIZI: Prescribing information, page 18, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=18)

## Components

<a id="skyrizi-inactive-ingredients"></a>

### What are the inactive ingredients in Skyrizi?

> “SKYRIZI 55 mg/0.37 mL prefilled syringe, 150 mg/mL prefilled pen or prefilled syringe, 180 mg/ 
> 1.2 mL prefilled syringe or prefilled cartridge, 360 mg/2.4 mL prefilled cartridge, and 600 mg/ 
> 10 mL vial inactive ingredients: glacial acetic acid, polysorbate 20, sodium acetate, trehalose, and 
> Water for Injection, USP.”

Source: [SKYRIZI: Prescribing information, page 46, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=46)

> “SKYRIZI (risankizumab-rzaa) injection 55 mg/0.37 mL prefilled syringe for subcutaneous use 
> Each SKYRIZI prefilled syringe contains a sterile, preservative-free, colorless to yellow, and 
> clear to slightly opalescent solution. Each syringe delivers 55 mg of risankizumab-rzaa and the 
> inactive ingredients glacial acetic acid (0.02 mg), polysorbate 20 (0.07 mg), sodium acetate 
> (0.28 mg), trehalose (23.4 mg), and Water for Injection, USP. The pH is 5.7.  
> SKYRIZI (risankizumab-rzaa) injection 150 mg/mL prefilled syringe or prefilled pen for 
> subcutaneous use 
> Each SKYRIZI prefilled pen or prefilled syringe contains a sterile, preservative-free, colorless to 
> yellow, and clear to slightly opalescent solution. Each syringe and pen delivers 150 mg of 
> risankizumab-rzaa and the inactive ingredients glacial acetic acid (0.054 mg), polysorbate 20 
> (0.2 mg), sodium acetate (0.75 mg), trehalose (63.33 mg), and Water for Injection, USP. The pH 
> is 5.7.”

Source: [SKYRIZI: Prescribing information, page 17, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=17)

Note: The first passage, from the Medication Guide, covers every presentation. The second gives the amounts per unit for the presentations used for plaque psoriasis: the 55 mg/0.37 mL prefilled syringe and the 150 mg/mL prefilled pen and syringe.

## Related pages
- [Medical information: Skyrizi (risankizumab-rzaa): Plaque psoriasis](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/access-and-coverage)
